Human leukocyte antigens in 295 Chinese patients with chronic myeloid leukemia

Experimental studies using synthetic peptides identical to the bcr-abl fusion region in chronic myeloid leukemia (CML) patients have revealed that some specific peptides could bind to human leukocyte antigen (HLA) class I and class II molecules. Previous clinical observations have also reported some significant HLA associations with the development of CML in their populations. Due to high diversity of HLA alleles, the present study assessed the possibility of an association of HLA molecules in CML patients living in Jiangsu province, the eastern part of China. HLA-A, B and DRB1 allele distributions in 295 CML patients (aged 4-65 years) were analysed and compared with unrelated healthy hematopoietic stem cell donors from the same ethnic and geographic background. By comparison of the HLA gene distribution characteristics between CML and healthy donor populations, differences with statistical significance were found in HLA-A*30 (5.42% versus 9.13%) with odds ratio (OR) 0.57, DRB1*07 (8.14% versus 12.51%; OR = 0.62), and B*81 (0.51% versus 0.09%, OR = 5.44). These results suggest that expression of HLA-A*30, DRB1*07 might imply a protective effect on CML acquisition, while B*81 might be associated with CML susceptive factors in our population.